Login to Your Account

Not a PD-1 after all? Medivation's DV9300 placed on partial hold

By Jennifer Boggs
Managing Editor

Monday, January 25, 2016

Medivation Inc. hit a little snag on the way to its pivotal phase II study testing supposed PD-1 inhibitor MDV9300 (pidilizumab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when the company concluded the drug does not actually inhibit PD-1 after all.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription